Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
34.55
+0.60 (1.77%)
At close: Feb 21, 2025, 4:00 PM
34.40
-0.15 (-0.43%)
After-hours: Feb 21, 2025, 6:57 PM EST
Apogee Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
1.97B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPGE News
- 19 days ago - Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis - GlobeNewsWire
- 24 days ago - Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Announces Agenda for Virtual R&D Day - GlobeNewsWire
- 3 months ago - Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - GlobeNewsWire
- 3 months ago - Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis - Seeking Alpha
- 3 months ago - Apogee Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 4 months ago - Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - GlobeNewsWire